Le Lézard
Classified in: Health, Science and technology
Subjects: Event, Trade Show, Webcast

Moderna to Present at Upcoming Investor Conferences in December 2020


Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming virtual investor conferences:

A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of each webcast will be archived on Moderna's website for 30 days following the presentation.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna's platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co., Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) and the Coalition for Epidemic Preparedness Innovations (CEPI). Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.


These press releases may also interest you

at 23:05
The mobile augmented reality market is expected to grow by USD 839.97 billion, progressing at a CAGR of over 94% during the forecast period. Click & Get Free Sample Report in Minutes The increasing dependence on apps and the proliferation of AR...

at 22:45
Syros Pharmaceuticals , a leader in the development of medicines that control the expression of genes, announced today that it has priced an underwritten public offering of 5,400,000 shares of common stock at a public offering price of $14.00 per...

at 21:52
In 2020, the global economy faced the impacts of the COVID-19 pandemic and the US-China trade war. While the economies around the world were critically affected, Taiwan was able to break through the predicament and make extraordinary performances in...

at 21:42
BioLineRx Ltd. , a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm commitment basis...

at 20:55
Kiromic BioPharma, Inc. , an immuno-oncology target discovery and gene-editing company, with a proprietary artificial intelligence neural network platform (Diamond AI) to develop novel oncology therapeutics, has announced the completion and...

at 20:45
The virtual Explore Waterloo Region esports camps will provide top level instruction to campers between the ages of 12-19, designed to help them improve their gaming abilities, while also building important life skills that extend beyond the game....



News published on 27 november 2020 at 13:05 and distributed by: